CD8+ T cell receptor complex recognizing Hepatitis C Virus peptide–MHC class I (HCV-specific TCR complex)

The CD8+ T cell receptor (TCR) complex recognizing Hepatitis C Virus (HCV) peptide–MHC class I is a specialized multi-protein assembly essential for the cellular immune response against HCV infection (NIH; PubMed PMID: 25108363). This complex consists of the TCR alpha and beta chains, which provide antigen specificity, associated with the CD3 signaling apparatus and the CD8 co-receptor that stabilizes the interaction with MHC class I molecules (UniProt). It functions by identifying specific viral epitopes, such as those derived from the NS3 or Core proteins, presented on the surface of infected hepatocytes (IEDB). Upon binding, the complex initiates a signaling cascade that leads to the secretion of pro-inflammatory cytokines like interferon-gamma and the direct killing of infected cells via perforin and granzymes (PubMed PMID: 30104634). In the context of chronic infection, this interaction is often impaired by T-cell exhaustion or viral mutational escape, making it a primary target for immunotherapeutic interventions (StatPearls). Current therapeutic strategies include the development of TCR-engineered T cells (TCR-T) and therapeutic vaccines designed to restore or enhance the recognition of these viral-MHC complexes to achieve viral clearance (Journal of Hepatology).

Other names

HCV-specific T-cell receptorHCV pMHC-TCR complexCD8+ TCR-HCV peptide-HLA complexHepatitis C virus-specific T-cell receptor

The TCR complex specifically binds to HCV-derived peptides presented by MHC class I molecules on the surface of infected hepatocytes, triggering downstream signaling through the CD3 complex and CD8 co-receptor to induce T-cell activation, proliferation, and targeted lysis of the infected cell.